Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Infect Chemother ; 19(1): 63-9, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22821355

RESUMEN

Hepatitis C virus (HCV) RNA values measured with two real-time PCR methods (Cobas Ampliprep/Cobas TaqMan, CAP/CTM, and the Abbott real-time PCR test, ART) vary among patients with genotype 1. We investigated HCV RNA values measured by two real-time PCR assays during pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy. We evaluated 185 cases of chronic hepatitis C patients, among which 97 patients received the PEG-IFN/RBV therapy. HCV RNA values of CAP/CTM for genotype 1 were significantly higher than those of ART (p < 0.05) The difference in HCV RNA values (CAP/CTM minus ART) of genotype 1 was significantly higher than those in genotype 2 (p < 0.0001). The positive rate (>0) of the difference of HCV RNA values in genotype 1 was 100 % (55/55), which was significantly higher than the 78.6 % (33/42) of genotype 2 (p < 0.001). There was no difference between TT and TG/GG genotype groups in terms of difference of HCV RNA values (CAP/CTM minus ART). After PEG-IFN/RBV therapy was administered, reduction of HCV measurements was observed from day 1 for both assays regardless of genotype. The HCV value of CAP/CTM during PEG-IFN/RBV therapy was consistently higher than the value of ART, although the difference in these two values gradually became smaller during the course of therapy, and eventually no significant difference was observed near the detection level. No correlation was observed between the sustained virological response (SVR) rate and the difference between the CAP/CTM HCV values and the ART HCV value before treatment.


Asunto(s)
Antivirales/uso terapéutico , Hepacivirus/genética , Hepatitis C Crónica/tratamiento farmacológico , ARN Viral/sangre , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Anciano , Antivirales/administración & dosificación , Esquema de Medicación , Quimioterapia Combinada , Femenino , Genotipo , Hepacivirus/clasificación , Hepacivirus/efectos de los fármacos , Hepatitis C Crónica/virología , Humanos , Interferón alfa-2 , Interferón-alfa/administración & dosificación , Interferón-alfa/uso terapéutico , Interferones , Interleucinas/genética , Masculino , Persona de Mediana Edad , Polietilenglicoles/administración & dosificación , Polietilenglicoles/uso terapéutico , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/uso terapéutico , Ribavirina/administración & dosificación , Ribavirina/uso terapéutico , Resultado del Tratamiento
2.
Gan To Kagaku Ryoho ; 35(1): 99-104, 2008 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-18195535

RESUMEN

In our institute, tacrolimus was started at a dose of 0.03 mg/kg/day and adjusted to maintain a blood concentration between 10 and 20 ng/mL combined with short term methotrexate after bone marrow transplantation from an unrelated donor. Dose adjustment was performed strictly, in order to prevent grade II-IV acute graft-versus-host disease (GVHD)while avoiding renal toxicity of tacrolimus. Then, in this study, we retrospectively evaluated the tacrolimus blood concentration during the first 4 weeks after transplantation. The mean tacrolimus concentration of the eligible 52 patients was 17.41+/-4.84(range, 9.5-33.4)ng/mL in the 1st week after transplantation, but declined to 13.7+/- 4.0(range, 8.1-25.6)ng/mL in the 2nd week. The dose of tacrolimus was decreased as follows: 0.022+/-0.005 mg/ kg/day(range 0.011-0.039)in the 1st week, and 0.018+/-0.007 mg/kg/day(range 0.004-0.040)in the 2nd week. The incidence of grade II-IV GVHD was 63.0% and grade III-IV was 13.9%. The individual variations of tacrolimus blood concentration did not affect the incidence of grade II-IV acute GVHD, as far as the concentration being maintained in the range of 14.82+/-4.22 ng/mL during the first 4 weeks after transplantation. In addition, the variations of tacrolimus concentration didn?t associate statistically with renal toxicity.


Asunto(s)
Trasplante de Médula Ósea , Tacrolimus/sangre , Adolescente , Adulto , Anciano , Trasplante de Médula Ósea/efectos adversos , Relación Dosis-Respuesta a Droga , Relación Dosis-Respuesta Inmunológica , Femenino , Enfermedad Injerto contra Huésped/tratamiento farmacológico , Enfermedad Injerto contra Huésped/inmunología , Humanos , Itraconazol/administración & dosificación , Masculino , Persona de Mediana Edad , Tasa de Supervivencia , Tacrolimus/administración & dosificación , Tacrolimus/farmacología , Factores de Tiempo , Donantes de Tejidos , Trasplante Homólogo/efectos adversos
3.
Biol Blood Marrow Transplant ; 13(1): 90-9, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17222757

RESUMEN

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-matched related donor has been suggested to improve the poor prognosis of adult T-cell leukemia/lymphoma (ATLL). However, the infusion of HTLV-I-infected cells from HTLV-I-positive related donors could lead to the development of donor-derived ATLL under immunosuppressive conditions. Although most ATLL patients lack a suitable HLA-matched related donor and require an HTLV-I-negative unrelated donor, little information is currently available regarding the outcome of unrelated bone marrow transplantation (UBMT) for ATLL. To evaluate the role of UBMT in treating ATLL, we retrospectively analyzed data from 33 patients with ATLL treated by UBMT through the Japan Marrow Donor Program (JMDP). Overall survival (OS), progression-free survival, and cumulative incidence of disease progression and progression-free mortality at 1 year after UBMT were 49.5%, 49.2%, 18.6%, and 32.3%, respectively. Multivariate analysis identified recipient age as an independent prognostic factor for OS (P = .044). Patients age >or=50 years who showed nonremission at transplantation tended to have higher rates of treatment-related mortality. Our observations suggest that UBMT could represent a feasible treatment option for ATLL patients and warrant further investigation based on these risk factors.


Asunto(s)
Trasplante de Médula Ósea , Trasplante de Células Madre Hematopoyéticas , Virus Linfotrópico T Tipo 1 Humano/patogenicidad , Leucemia-Linfoma de Células T del Adulto/terapia , Adulto , Femenino , Supervivencia de Injerto , Enfermedad Injerto contra Huésped , Efecto Injerto vs Leucemia/inmunología , Humanos , Japón , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Análisis de Supervivencia , Trasplante Homólogo
4.
Int J Hematol ; 85(1): 85-8, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17261507

RESUMEN

We describe the case of a 38-year-old male patient who had acute myeloid leukemia and developed prolonged neutropenia after induction chemotherapy. He developed thrombotic complications at multiple sites. Thrombophlebitis of the hemorrhoidal plexus became exacerbated and developed into critical cellulitis. Because the patient had no human leukocyte antigen-identical sibling, we considered an alternative donor. Because of the necessity for early neutrophil recovery to resolve the critical infection, we proceeded with allogeneic peripheral blood stem cell transplantation (PBSCT) from a microchimeric haploidentical sibling donor. We infused peripheral blood mononuclear cells directly into the patient without cryopreservation and thawing procedures. We aimed for the contaminating granulocytes to act as a granulocyte transfusion. Actually, the neutrophils increased to 1.6 x 10(9)/L on day 1, when the patient showed a temporary resolution of infection. Engraftment was achieved shortly after neutropenic nadir, and acute graft-versus-host disease (GVHD) has been well controlled. Although the patient experiences extensive chronic GVHD, he has been well as an outpatient with a 90% Karnofsky performance status score. The leukemia has been in complete remission for more than 1 year. These findings suggest the clinical utility of a salvage therapy with allogeneic PBSCT from a microchimeric haploidentical donor to treat refractory leukemia concurrent with life-threatening infection.


Asunto(s)
Celulitis (Flemón)/etiología , Leucemia Mieloide/complicaciones , Leucemia Mieloide/terapia , Trasplante de Células Madre de Sangre Periférica/métodos , Terapia Recuperativa/métodos , Tromboflebitis/etiología , Enfermedad Aguda , Adulto , Supervivencia sin Enfermedad , Enfermedad Injerto contra Huésped , Granulocitos , Humanos , Infecciones , Masculino , Hermanos , Donantes de Tejidos , Trasplante Homólogo , Gemelos Monocigóticos
5.
Can J Ophthalmol ; 41(4): 472-5, 2006 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16883364

RESUMEN

CASE REPORT: Although ocular complications associated with graft-versus-host disease (GVHD) can include corneal dysfunction, corneal perforation is not common. We report the presence of apoptotic cells in a perforated cornea of a patient with GVHD. A 72-year-old man with the angioimmunoblastic type of malignant lymphoma developed chronic GVHD after allogeneic peripheral blood stem cell transplantation. Despite systemic and topical treatment, both corneas perforated, and penetrating keratoplasty with cataract extraction and intraocular lens implantation was performed on both eyes. COMMENTS: The corneal button excised from the right eye was examined histologically and stained for apoptotic cells by TdT-mediated dUTP nick end labeling (TUNEL). This revealed thinning of the epithelial cell layer and stroma, with cells, including lymphocytes, infiltrating to the site of the perforation. Some of the epithelial cells and keratocytes were TUNEL positive. The presence of apoptotic cells in our case suggests that apoptosis may be involved in the perforation of the cornea in patients with GVHD.


Asunto(s)
Apoptosis , Enfermedades de la Córnea/etiología , Enfermedades de la Córnea/patología , Enfermedad Injerto contra Huésped/complicaciones , Anciano , Extracción de Catarata , Enfermedad Crónica , Sustancia Propia/patología , Epitelio Corneal/patología , Fibroblastos/patología , Trasplante de Células Madre Hematopoyéticas , Humanos , Linfadenopatía Inmunoblástica/terapia , Etiquetado Corte-Fin in Situ , Queratoplastia Penetrante , Implantación de Lentes Intraoculares , Masculino , Rotura Espontánea
6.
Eur J Haematol ; 75(2): 167-70, 2005 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16000134

RESUMEN

A 38-year-old woman was admitted with superior mesenteric vein (SMV) thrombosis, which was refractory to anticoagulation therapy. The plasma antithrombin activity was decreased and hardly compensated by concentrated antithrombin preparation due to high consumption rate. However, successful anticoagulation was achieved by administration of direct thrombin inhibitor, argatroban. Family studies of antithrombin activity revealed that she had type I congenital antithrombin deficiency. A novel heterozygous mutation in the gene for antithrombin (single nucleotide T insertion at 7916 and 7917, Glu 272 to stop in exon 4) was identified. Argatroban administration would be effective in the treatment of congenital antithrombin deficiency with SMV thrombosis.


Asunto(s)
Deficiencia de Antitrombina III/complicaciones , Oclusión Vascular Mesentérica/tratamiento farmacológico , Ácidos Pipecólicos/administración & dosificación , Trombosis de la Vena/tratamiento farmacológico , Adulto , Deficiencia de Antitrombina III/congénito , Deficiencia de Antitrombina III/genética , Arginina/análogos & derivados , Análisis Mutacional de ADN , Femenino , Mutación del Sistema de Lectura , Heterocigoto , Humanos , Venas Mesentéricas , Terapia Recuperativa , Sulfonamidas , Resultado del Tratamiento
7.
Rinsho Ketsueki ; 45(6): 478-80, 2004 Jun.
Artículo en Japonés | MEDLINE | ID: mdl-15287525

RESUMEN

The Kyushu Hematology Organization for Treatment (K-HOT) Study Group was organized in 1999 to study hematological disorders diagnosed in the participating institutions in the Kyushu district. We registered all new patients with hematological disorders and from February 2000 to the end of 2003, a total of 2908 patients had been registered. They include non-Hodgkin's lymphoma in 803 patients, leukemia in 556, multiple myeloma (MM) in 276, myelodysplastic syndrome in 273, and adult T-cell leukemia/lymphoma (ATL) in 269 followed in a decreasing order by idiopathic thrombocytopenic purpura, aplastic anemia, and other benign hematological disorders and myeloproliferative disorders. The annual incidence of MM is estimated to be much higher than that previously reported. It is also confirmed that ATL is still one of the frequently encountered lymphoid malignancies in the Kyushu district.


Asunto(s)
Enfermedades Hematológicas/epidemiología , Sistema de Registros , Femenino , Humanos , Japón/etnología , Leucemia/epidemiología , Masculino , Sociedades Médicas
8.
Int J Hematol ; 80(5): 441-8, 2004 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-15646657

RESUMEN

Cytomegalovirus (CMV)-specific immune reconstitution early after stem cell transplantation (SCT) was evaluated prospectively by detecting CD8+ T-cells, which recognize the peptide QYDPVAALF in the context of HLA-A*2402. Fifteen allogeneic SCT recipients were included in the study. All recipients and donors were seropositive for CMV and had the HLA-A*2402 allele. CMV-specific T-cells were detected as early as 1 month after transplantation, and their numbers increased to peak levels 2 to 5 months after transplantation. The numbers of CMV-specific T-cells in patients who developed grade II to IV acute graft-versus-host disease (GVHD) and received corticosteroids for acute GVHD were low in the early period after allogeneic SCT. There was a trend toward earlier reconstitution of CMV-specific CD8+ T-cells in allogeneic peripheral blood SCT (PBSCT) patients than in allogeneic bone marrow transplantation patients. The contribution of T-cells in the graft to the recovery of CMV-specific immune responses was also suggested by the finding that the reconstitution of CMV-specific CD8+ T-cells was delayed in CD34-selected autologous PBSCT compared with unpurged autologous PBSCT. The reconstitution of CMV-specific CD8+ T-cells was delayed in patients with CMV disease or recurrent CMV reactivation. These observations suggest that the detection of CMV-specific T-cells with an HLA-peptide tetramer is useful to assess immune reconstitution against CMV and to identify patients at risk for CMV disease or recurrent CMV reactivation after SCT.


Asunto(s)
Linfocitos T CD8-positivos/inmunología , Infecciones por Citomegalovirus/inmunología , Citomegalovirus/inmunología , Antígenos HLA-A/inmunología , Trasplante de Células Madre Hematopoyéticas , Oligopéptidos/inmunología , Corticoesteroides/uso terapéutico , Adulto , Anciano , Antígenos CD34/inmunología , Proliferación Celular , Femenino , Enfermedad Injerto contra Huésped/tratamiento farmacológico , Enfermedad Injerto contra Huésped/inmunología , Humanos , Leucemia Linfoide/terapia , Leucemia Mieloide/terapia , Linfoma no Hodgkin/terapia , Masculino , Persona de Mediana Edad , Trasplante Homólogo
11.
Intern Med ; 42(1): 98-101, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12583628

RESUMEN

The association of malignancy with nephrotic syndrome and renal histopathologic abnormalities is well documented. We report a case of intravascular lymphomatosis (IVL) presenting as nephrotic syndrome which was diagnosed by renal biopsy. Histological examination of the renal biopsy specimens showed dissemination of neoplastic lymphoid cells throughout the glomerular capillary bed. These tumor cells were positive for CD20. Since the nephrotic syndrome improved with treatment of the lymphoma, intravascular lymphomatosis may well have played an important role in the pathogenesis of minimal change nephrotic syndrome in this patient.


Asunto(s)
Linfoma de Células B/complicaciones , Síndrome Nefrótico/etiología , Neoplasias Vasculares/complicaciones , Humanos , Glomérulos Renales/patología , Neoplasias Renales/complicaciones , Neoplasias Renales/diagnóstico , Neoplasias Renales/patología , Linfoma de Células B/diagnóstico , Linfoma de Células B/patología , Masculino , Microscopía Electrónica , Persona de Mediana Edad , Síndrome Nefrótico/diagnóstico , Síndrome Nefrótico/patología , Neoplasias Vasculares/diagnóstico , Neoplasias Vasculares/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA